根治性治疗的胃癌患者中同时性和异时性其他原发性癌症的临床影响。
The Clinical Impact of Synchronous and Metachronous Other Primary Cancer in Gastric Cancer Patients Who Receive Curative Treatment.
机构信息
Department of Surgery, Yokohama City University, Yokohama, Japan;
Department of Gastrointestinal Surgery, Kanagawa Cancer Center, Yokohama, Japan.
出版信息
In Vivo. 2022 Sep-Oct;36(5):2514-2520. doi: 10.21873/invivo.12987.
BACKGROUND/AIM: The present study evaluated the clinical characteristics and prognostic factors of gastric cancer (GC) patients with synchronous and metachronous other primary cancer who received curative treatment for GC.
PATIENTS AND METHODS
The study included 244 patients who underwent curative treatment for GC between 2005 and 2018. The risk factors for the overall survival (OS) and recurrence-free survival (RFS) were identified.
RESULTS
A total of 244 patients were included in this study. Among them, 58 patients were diagnosed with synchronous and metachronous other primary cancer. When comparing the patient background characteristics and clinical course between GC patients without and with synchronous and metachronous other primary cancer, the background, postoperative surgical complications, and details of adjuvant treatment were similar between the two groups. The 3- and 5-year OS rates in GC patients with synchronous and metachronous other primary cancer were 69.7% and 48.0%, respectively, while those in patients without synchronous and metachronous other primary cancer were 80.6% and 74.3%, respectively, showing a statistically significant difference (p<0.001) The synchronous and metachronous other primary cancer status was included in the final multivariate analysis model (hazard ratio=2.201; 95% confidence interval=1.229-3.942; p=0.008).
CONCLUSION
Synchronous and metachronous other primary cancer status is a prognostic factor in GC patients. Therefore, synchronous and metachronous other primary cancer patients need both other primary cancer and GC follow-up to improve their survival.
背景/目的：本研究评估了接受 GC 根治性治疗的同时性和异时性多原发癌胃癌（GC）患者的临床特征和预后因素。
患者与方法
本研究纳入了 2005 年至 2018 年间接受 GC 根治性治疗的 244 例患者。确定了总生存期（OS）和无复发生存期（RFS）的危险因素。
结果
本研究共纳入 244 例患者。其中，58 例患者被诊断为同时性和异时性多原发癌。在比较 GC 患者与无同时性和异时性多原发癌患者的背景特征和临床过程时，两组患者的背景、术后手术并发症和辅助治疗细节相似。同时性和异时性多原发癌 GC 患者的 3 年和 5 年 OS 率分别为 69.7%和 48.0%，而无同时性和异时性多原发癌患者的 3 年和 5 年 OS 率分别为 80.6%和 74.3%，差异有统计学意义（p<0.001）。同时性和异时性多原发癌状态被纳入最终多变量分析模型（风险比=2.201；95%置信区间=1.229-3.942；p=0.008）。
结论
同时性和异时性多原发癌状态是 GC 患者的预后因素。因此，同时性和异时性多原发癌患者需要同时关注其他原发性癌症和 GC 的随访，以提高其生存率。
Zotero 插件